KR101069844B1 - A composition for the prevention and treatment of edema or dermatitis containing Angelica decursiva extract or fraction thereof as an active ingredient - Google Patents

Abstract

The present invention relates to a composition for the prevention or treatment of edema or dermatitis, which contains a body sprout ( Magnetica , Angelica decursiva, Peucedanum decursivum ) extract or a fraction thereof as an active ingredient, the body of the present invention (Magnetica) extract or a fraction thereof Silver inhibits the production or secretion of cytokines and chemokines, which are inflammatory mediators, and suppresses edema, so that the composition containing the active ingredient can be usefully used for the prevention or treatment of edema or dermatitis.

Body sprouts, Angelica decursiva, Peucedanum decursivum, Self-protection, Edema, Dermatitis, Cytokines, Chemokines

Description

A composition for the prevention and treatment of edema or dermatitis containing Angelica decursiva extract or fraction amounts as an active ingredient}

The present invention relates to a composition for the prophylaxis or treatment of edema or dermatitis containing the extract of the body herbs (magnetism, Angelica decursiva, Peucedanum decursivum ) as an active ingredient.

Dermatitis is an inflammation occurring on the skin and is roughly divided into atopic dermatitis, contact dermatitis and seborrheic dermatitis. This inflammation is one of tissue damage, external stimuli, or the defense response of biological tissues to various infectious agents, and enzyme activation, inflammatory mediator secretion, cellular activation of various inflammatory mediators and various immune cells in blood vessels and body fluids. A series of complex pathologies, including infiltration and fluid effusion, circulatory disorders, tissue degeneration and hyperproliferation. In the inflammatory process, macrophages initially gather in the wound and attack the invading bacteria, and then plasma builds up in the wound and increases blood flow, causing external symptoms such as fever, erythema, edema, and pain. . If these inflammatory reactions occur continuously or excessively, they proceed to the main pathology of the disease (sensitized allergic disease, chronic inflammatory disease) and cause severe abnormal disorders.

Non-steroidal anti-inflammatory drugs (NSAIDS), a widely used drug for the treatment of most inflammatory diseases, are produced from prostaglandin from arachidonic acid called cyclooxygenase (COX). By inhibiting the enzyme activity involved in the biosynthesis of the drug, it exhibits anti-inflammatory action, which causes serious side effects such as gastrointestinal disorders, liver disorders, and renal disorders in addition to the main therapeutic effects, and thus is restricted in long-term use (Rajakariar R et. al. 2006). Therefore, the development of a new anti-inflammatory analgesic that is excellent in anti-inflammatory efficacy without any difficulty for long-term use with little side effects is widely required, which is also a reason for the recent active research on material development through verification of efficacy from natural resources.

Various biochemical phenomena are involved as a cause of inflammation in living bodies. Macrophage (Macrophage) is a cell with a variety of functions to produce various cytokines and NO by chemical stimulation plays an important role in the inflammatory response. In particular, inducible nitrogen oxide synthase (iNOS) expressed by cytokine stimulation such as lipopolysaccharide (LPS), interferonγ, and TNF-α in macrophages produces a large amount of NO. This oxidative stress is known to promote NFκB activity, a transcription factor of the inflammatory response inhibited by IκB. Activated NFκB is known to promote the expression of genes that induce inflammatory reactions such as iNOS, COX-2 and various cytokines such as IL-1β or TNF-α. (Baeuerle et al. , Annu. Rev. Immunol., 12: 141-179, 1994).

Nitric oxide (NO) is produced from L-arginine by three major nitrogen oxide synthase (NOS) isomers, neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS). nNOS and eNOS are regulated by Ca ²⁺ / calmodulin, but iNOS is regulated at the level of transcription by inflammatory stimuli such as interleukin, interferon, LPS. Small amounts of NO produced by nNOS or eNOS are responsible for normal physiological functions such as vasodilation, neurotransmission, and cellular destruction of pathogens, whereas NO produced by iNOS in macrophages is associated with various pathophysiology, including inflammation and cancer. It is involved in the process and reacts with superoxide to form peroxynitrite, which acts as a powerful oxidant, damaging cells and activating NFκB in macrophages activated by inflammatory stimuli. , Cancer, arteriosclerosis and the like (Lawrence et al. , Nat Med., 7: 1291-1297, 2001; Riehemann et al. , FEBS Lett., 442: 89-94, 1999; et al. , Science, 258: 1898-1902, 1992).

Prostaglandins are unsaturated fatty acid derivatives containing 20 carbons with a cyclic structure. They are mainly chemical transporters involved in chronic inflammatory diseases and are also involved in autoimmune diseases such as asthma (Ruf el al. , Eur. J. Biochem., 204: 1069-1073, 1992). Prostaglandins are biosynthesized by COX, which has two isomers: COX-1 and COX-2 (Smith et al. , J. Biol. Chem., 271: 33157-33160, 1996). COX-1 is an enzyme that is constantly present in tissues such as the stomach and kidneys, and is involved in maintaining normal homeostasis, whereas COX-2 is transiently and rapidly expressed in cells by cell division factors or cytokines during inflammation and other immune responses. do. NSAIDs, which are used to treat chronic inflammatory diseases such as acute or rheumatoid arthritis, are known to exhibit several side effects, such as gastrointestinal disorders, by inhibiting COX-2 enzymes as well as COX-1 enzymes. Masferrer et al. , P. Natl. Acad. Sci. USA., 91: 3228-3232, 1994).

Therefore, searching for a substance that inhibits tumor necrosis factor (TNF-α) and nitrogen oxide (NO) production, inhibits prostaglandin production, or inhibits the production of IL-1β may prove to be an effective substance for edema or dermatitis. There will be.

On the other hand, the body sprout is a perennial plant of the dicotyledon plant Umbelliferae, scientific name is Angelica decursiva , also called Peucedanum decursivum . It is 80 ~ 150cm in size, distributed in Korea, Japan, China, etc., and lives near wetlands of mountains and fields. In Chinese medicine, the roots of body herbs are called Jahwajeonjeon (紫花 前胡), and the roots of Jahwajeon and Pehwadanum praeruptorum are called Jeonho (전 胡). It is known to be effective in asthma, etc. However, there have been no studies or reports on the effect of the body herb extract on skin inflammatory diseases.

Thus, the present inventors confirmed that the extract of the body sprouts (magnetism protector) or fractions thereof inhibits the production or secretion of the inflammatory mediators cytokines and chemokines and has an excellent edema inhibitory effect in animal inflammatory disease models. The present invention has been completed.

It is an object of the present invention to provide a composition for preventing or treating edema or dermatitis, which contains the extract of Botanus herb (magnetism protector) or a fraction thereof as an active ingredient.

In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of edema, containing the body sprouts (magnetism) extract or a fraction thereof as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating dermatitis, which contains the extract of Botanical Herb (Magneticaea) or a fraction thereof as an active ingredient.

The present invention also provides a method for treating edema, comprising administering to the subject an pharmaceutically effective amount of the extract of Bodhi or Jamaican.

The present invention also provides a method of treating dermatitis, comprising administering to a subject a pharmaceutically effective amount of the extract of Bodhi or Jamaican.

The present invention also provides a method for preventing edema, comprising administering to the subject an pharmaceutically effective amount of the extract of Bodhi or Jamaican.

In addition, the present invention provides a method for preventing dermatitis, comprising administering to a subject a pharmaceutically effective amount of the extract of Botanicals (Magneticaea) or a fraction thereof.

Furthermore, the present invention provides a health food composition for preventing or improving edema or dermatitis, which comprises the extract of Botanical Herb (Magneticaea) or a fraction thereof as an active ingredient.

In addition, the present invention provides a cosmetic composition for the prevention or improvement of edema or dermatitis comprising the extract or the fraction thereof as an active ingredient.

The present invention relates to a composition for the prevention or treatment of edema or dermatitis, containing a body herb (self-protection) extract or a fraction thereof as an active ingredient, wherein the body herb (self-protection) extract or a fraction thereof is lipopolysaccharide (LPS) Tumor necrosis factor-α (TNF-α), interleukin (Interleukin-1β, IL-1β), which are inflammatory cytokines and chemokines with increased secretion from macrophage by Inhibits the production of nitric oxide (NO) and prostaglandin (E ₂ , PGE ₂ ) and induces phorbol myristate acetate (PMA, 12- O- Tetradecanoylphorbol-13-acetate (TPA)) Since one animal model of inflammatory disease effectively inhibits inflammatory edema, it can be usefully used to prevent or treat edema or dermatitis.

Hereinafter, the present invention will be described in detail.

The present invention provides a pharmaceutical composition for the prevention or treatment of edema or dermatitis, which contains the extract of the body sprouts (magnetism) or a fraction thereof as an active ingredient.

Dermatitis targeted by the present invention is characterized in that it is selected from the group consisting of edema, hypersensitivity, allergic dermatitis, contact dermatitis, atopic dermatitis, skin allergy and urticaria, but is not limited thereto.

Body herb (magnetization) extract of the present invention can be prepared by a manufacturing method comprising the following steps:

1) preparing a extract by extracting the dried body sprouts (magnetization signal) with an extraction solvent;

2) filtering the extract of step 1); And

3) preparing an extract by concentrating and drying the filtered extract of step 2) under reduced pressure;

In the above production method, the body sprouts (magnetization sign) of step 1) can be used without limitation, such as those grown or commercially available. The body sprouts (magnetization) can use all of the outposts, leaves, stems, roots, but it is preferable to use the roots (hojeon).

The extraction solvent is preferably water, alcohol or a mixture thereof. It is preferable to use C ₁ ~ C ₄ lower alcohol as the alcohol, it is preferable to use ethanol or methanol as the lower alcohol. The extraction solvent is preferably extracted by adding 5 to 15 times the amount of dried magnetized rice, and more preferably by adding 10 times the extraction solvent. The extraction temperature is preferably 40 ~ 80 ℃, more preferably 50 ~ 60 ℃ but is not limited thereto. In addition, the extraction time is preferably 2 to 6 hours, more preferably 2 hours is not limited thereto. In addition, the extraction number is preferably 1 to 5 times, but is not limited thereto.

In the above production method, the decompression concentration of step 3) is preferably a rotary vacuum concentrator, but is not limited thereto. In addition, the drying may be hot air drying, vacuum drying or lyophilization, all of which is preferably lyophilization, but is not limited thereto.

The body herb (magnetization) fraction of the present invention may be obtained by suspending the body herb (magnetization) extract in water, and then sequentially fractionating the extract with a solvent having a different polarity. The solvent is preferably n-hexane, methylene chloride, dichloromethane, ethyl acetate, n-butanol, water (H ₂ O), but is not limited thereto. It doesn't happen.

In the present invention, the tumor necrosis factor (TNF-α), interleukin-1β (IL-1β), nitrogen oxides (TNF-α) targeting RAW 264.7 macrophage line in order to determine the effect on the dermatitis of the extract of the body sprouts NO), the inhibitory effect of the production of prostaglandin E ₂ (PGE ₂ ) and cytotoxicity evaluation experiments were performed.

As a result, the extract of the body sprouts (magnetism) or its fractions was not cytotoxic at all (see Fig. 1). In addition, it was confirmed that significantly inhibit the production and secretion of inflammatory cytokines and chemokines TNF-α, IL-1β, NO, PGE ₂ (see Figs. 2 to 5).

In addition, mice were induced with inflammatory edema with terephthalic acid (12-O-Tetrade-canoylphobol 13-acetate (TPA)) in dermatitis-related edema-induced animal model experiments, and the extracts were administered with anti-magnetizing extract. As a result, the thickness of the edema was reduced compared to the control when the body herb (self-protection) extract of the present invention was able to confirm the edema inhibitory effect (see FIGS. 6 and 7).

In the case of using the medicinal herbs or extracts of the present invention as a medicine, it may further contain one or more active ingredients exhibiting the same or similar functions.

The body sprouts (magnetism) extract or fractions thereof may be administered orally or parenterally during clinical administration and may be used in the form of general pharmaceutical preparations.

In other words, the extract of the body of the present invention or the fraction thereof may be administered in a variety of oral and parenteral formulations in actual clinical administration, when formulated, commonly used fillers, extenders, binders, wetting agents, shelf life It is formulated using diluents or excipients such as release, surfactants and the like. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate ( It is prepared by mixing Calcium carbonate, Sucrose or Lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The dosage of the extract of the present invention or fractions thereof varies depending on the body weight, age, sex, health condition, diet, time of administration, method of administration, excretion rate and severity of the disease, and the daily dosage is body herbs. It is 0.1 to 100 mg / kg, preferably 30 to 80 mg / kg, more preferably 50 to 60 mg / kg, and may be administered 1 to 6 times a day, based on the amount of the (Self-protection) extract. .

Extracts or fractions thereof of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers.

The present invention also provides a method for treating edema or dermatitis, comprising administering to the subject an pharmaceutically effective amount of the extract of Bodhisulfaceae (magnetism) or a fraction thereof.

The present invention also provides a method for preventing edema or dermatitis, comprising administering to a subject a pharmaceutically effective amount of the extract of Bodhisporum (Magneticaea) or a fraction thereof.

At this time, the pharmaceutically effective amount is preferably 0.1 to 500 mg / kg more preferably 1 to 100 mg / kg, but is not limited thereto. The dosage may vary depending on the weight, age, sex, health status, diet, duration of administration, method of administration, elimination rate, severity of disease, and the like of a particular patient.

In addition, the present invention provides a health food composition for the prevention or improvement of edema or dermatitis containing the body sprouts (magazine) extract or fractions thereof as an active ingredient.

In the case of using the extract of the present invention or the fractions thereof as a food additive, the extract may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, in the preparation of food or beverages, the composition of the present invention is added in an amount of up to 15 parts by weight, preferably up to 10 parts by weight based on the raw materials. However, in the case of long-term intake for health and hygiene or health control, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety. .

There is no particular limitation on the kind of food. Examples of the food to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include healthy foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.

In addition to the above, the extract of the present invention or fractions thereof may be used in various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the extract of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

In addition, the present invention provides a cosmetic composition for the prevention and improvement of edema or dermatitis containing the above-mentioned body sprouts (magazine) extract or fractions thereof as an active ingredient.

The cosmetics prepared by containing the extract of the body of the present invention (magnetization protector) or a fraction thereof as an active ingredient can be prepared in the form of a general emulsion formulation and solubilized formulation. Cosmetics of the emulsified formulations include nutrient cosmetics, creams, essences, etc., and cosmetics of the solubilized formulations are flexible cosmetics.

Suitable cosmetic formulations include, for example, emulsions, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes), nonionic vesicles obtained by dispersing an oil phase in a solution, gel, solid or pasty anhydrous product, aqueous phase, for example. It may be provided in the form of a dispersant, cream, skin, lotion, powder, ointment, spray or cone stick. It may also be prepared in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.

In addition to the extract of the present invention or fractions thereof, the cosmetics may further contain fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants. Commonly used in water, ionic or nonionic emulsifiers, fillers, metal-ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or cosmetics It may contain adjuvants conventionally used in the cosmetic field such as any other ingredients used.

Hereinafter, the present invention will be described in detail by Examples, Experimental Examples and Formulation Examples.

However, the following Examples, Experimental Examples, and Formulation Examples specifically illustrate the present invention, and the content of the present invention is not limited to Examples, Experimental Examples, and Formulation Examples.

Example 1 Preparation of Botanical Herb (Magneticaea) Extract and Fractions thereof

<1-1> Preparation of Extract

The roots of the body sprouts ( Jehwahwa Lake, Angelica decursiva, Peucedanum decursivum ) collected in Mukgok -ri, Gonyang -myeon, Sacheon-si, Gyeongsangnam-do , were dried and ground. 100 g of the crushed body sprouts (magnetization precursor) were immersed in 70% ethanol aqueous solution, 100% ethanol, 100% methanol, or 1 liter of water and stirred well, and then heated to reflux for 2 hours at 50 to 60 ° C. Extracted and filtered on filter paper. The extract was concentrated under reduced pressure using a concentrator at 50 to 55 ° C., and then freeze-dried to obtain an extract of the body sprouts. As a result, solvent extracts of 70% ethanol (14 g), 100% ethanol (15 g), 100% methanol (14 g) and water (20 g) could be prepared, respectively.

<1-2> Preparation of Fractions

After 250 g of the 70% ethanol extract prepared in Example 1-1 was suspended in 1 liter of water (H ₂ O), the suspension and the same amount of n-hexane were added thereto, followed by the water layer and the n-hexane layer. It was left to separate. After chemical equilibrium, the n-hexane layer was separated and a new amount of n-hexane was poured again and left to separate into an aqueous layer and an n-hexane layer. The n-hexane layer obtained by repeating the layer separation process three times was concentrated under reduced pressure to obtain an n-hexane (hexane, Hx) fraction.

Methylene chloride (dichloromethane, Mc), ethyl acetate (EA), n-butanol (BuOH), water (H ₂ O) according to the polarity of the solvent in the water layer again A total of five fractions were obtained by systematic phylogenetic fraction extraction. As a result, fractions of n-hexane (14 g), methylene chloride (16 g), ethyl acetate (5 g), n-butanol (182 g) and water (12 g) could be prepared, respectively.

Experimental Example 1: Measurement of Cytotoxicity

In order to confirm the safety of the extracts and fractions of the body sprouts (magnetization signal) prepared in Example 1, the cytotoxicity experiment by MTT assay was performed using 70% ethanol extract. Mouse macrophage RAW 264.7 cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA) and added 10% fetal bovine serum (FBS), 100 units / mL penicillin, and 100 μg / mL streptomycin. Incubated in DMEM medium at 37 ℃, 5% CO ₂ environment.

Samples were treated in RAW 264.7 macrophages by concentration (0, 50, 100, 200 μg / mL) and incubated for 24 hours, followed by 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium Bromide (MTT; 500 μg / mL) was added and reacted at 37 ° C. for 1 hour. After removing all of the culture medium and dimethyl sulfoxide (DMSO) solution was added to dissolve the resulting formazan (formazan), the absorbance was measured at 570 nm. Relative cell viability (% of control) was calculated by comparing the measured value with the control. In the sample, the chopped (subtotal) extract used 70% ethanol extract.

As a result, as shown in Figure 1, the extract of the body sprouts (magnetism), hexane fraction (Hx), methylene chloride fraction (Mc), ethyl acetate fraction (EA), butanol fraction (BuOH), water fraction (H ₂ O ) There was no significant difference compared to the control at concentrations of 0 to 200 μg. Therefore, it was confirmed that the extracts and fractions of the body sprouts (magnetions) of the present invention are not cytotoxic.

Experimental Example 2 Measurement of Inhibitory Effect of Inflammatory Cytokines and Chemokines

To investigate the inhibitory effect on the inflammatory triggers of the extracts and fractions of the body of the present invention. Specifically, lipopolysaccharide (LPS) (1 μg / mL) and sample (100 μg / mL) were treated on RAW264.7 macrophages and cultured for 20 hours, followed by inflammatory cytokines (cytokine) secreted in the medium. And chemokines (tumok necrosis factor-α, TNF-α), interleukin (Interleukin-1β, IL-1β), nitric oxide (NO), prostaglandin E ₂ , PGE ₂ ) The amount of was analyzed by ELISA kit or NO colorimetric assay kit (R & D Systems Inc., Minneapolis, MN, USA). The 100% production amount was defined as the LPS-treated group, and the relative% of control of the sample treatment group was calculated. All measurement results were expressed as mean and standard error (SE), and the difference between the groups was statistically analyzed using Student's t-test to determine significance.

As a result, as shown in Figure 2, in the case of tumor necrosis factor (TNF-α), the extract of the body sprouts (magnetism) showed a 25.1% inhibition of the production compared to the control group, and even in the case of fractions It was. In particular, the ethyl acetate fraction (EA) of the fraction showed the most excellent production inhibitory effect of 61.3%.

In addition, as shown in Figure 3, in the case of interleukin-1β (IL-1β), the extract of the body sprouts (magnetism) showed a 23.5% inhibitory effect of the production compared to the control, and the fraction showed a significant inhibitory effect. In particular, the methylene chloride fraction (Mc) in the fraction showed a high production inhibitory effect of 58.5%.

In the case of nitrogen oxide (NO), as shown in Figure 4, the extract of the body sprouts (magnetism) showed a 15.1% inhibitory effect compared to the control, methylene chloride fraction (Mc) of the fraction of 42.9% It showed a high production inhibitory effect.

In the case of prostaglandin E ₂ (PGE ₂ ), as shown in Figure 5, the extract of the body sprouts (magnetization) showed a production inhibition effect of 65.4% compared to the control, methylene chloride fraction (Mc) of the fraction 86.0 High production inhibitory effect was shown.

As a result of the above experiments, the extracts and fractions of the body sprouts of the present invention inhibit the production and secretion of inflammatory cytokines and chemokines TNF-α, IL-1β, NO, and PGE ₂ , thereby helping to prevent or treat dermatitis. I think this will be.

Experimental Example 3: measurement of the effect of suppressing edema

<3-1> experimental animals and breeding conditions

The 8-week-old ICR mouse, Daehan Biolink Co., Ltd., the experimental animal most frequently used as an inflammatory animal model, is adapted to the environment where the contrast is controlled at 20-22 ° C, 40-60% relative humidity, and 12 hour intervals. In order to observe the visual symptoms, only normal animals were selected, and 10 animals were randomly distributed to each group and used in the experiment.

<3-2> Animal Model for Ear Edema Inflammation

Inflammatory edema was induced by applying phorbol myristate acetate (PMA, 12- O- Tetradecanoylphorbol-13-acetate, TPA) (1 μg / 20 μl of acetone) to the right ear of the experimental animal, and to the left ear. Only excipients (20 μl of acetone) were applied and used as an inflammatory animal model (Yasukawa K et al. 2008). On the other hand, 30 minutes before TPA induced inflammatory edema, a sample (1 mg / ear) dissolved in MeOH-CHCl ₃ -H ₂ O (2: 1: 1) was applied to the ear of the experimental group, and indomethacin as a positive control group. (0.3 mg / ear) and MeOH-CHCl ₃ -H ₂ O (2: 1: 1) were applied in the same manner as the negative control.

<3-3> Inflammatory edema inhibition rate measurement

Inflammation was accompanied by TPA as described above in Experimental Example <2-2>, followed by 6 hours, and after anesthesia of the experimental animals, the thickness of each ear was measured with a micrometer to calculate the increase rate as an inflammatory edema index. It was. 100% edema rate was defined as a group treated with only phorbol myristate acetate (PMA, 12- O- Tetradecanoylphorbol-13-acetate, TPA) to give a relative% of control. All measurement results were expressed as mean and standard error (SE), and the difference between the groups was statistically analyzed using Student's t-test to determine significance.

As a result of the experiment, it was confirmed that the extract of the body sprouts (magnetism) has excellent anti-inflammatory activity in the animal inflammatory disease model. In detail, the edema thickness of the control group animals treated with TPA was 35.2 mm, but the edema thickness was 14.4 to 24.2 mm when treated with the extract of Jahojeon, showing an inhibition rate of edema of 19.3 to 59.1% (see FIGS. 6 and 7). ). Therefore, it was confirmed that the extract of the body sprouts (magnetism) of the present invention has an effect of preventing or treating inflammatory edema.

Examples of formulations for the composition of the present invention are illustrated below.

Preparation Example 1 Preparation of Pharmaceutical Formulation

The pharmaceutical preparations comprising the extract of the body of the present invention (magnetism) or fractions thereof were prepared as follows.

1. Preparation of powder

2 g of the extract of Example 1 or a fraction thereof

1g lactose

The above components were mixed and packed in airtight bags to prepare powders.

2. Preparation of Tablets

100 mg of the extract of Example 1 or a fraction thereof

Corn Starch 100mg

Lactose 100mg

2 mg magnesium stearate

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

3. Preparation of Capsule

100 mg of the extract of Example 1 or a fraction thereof

Corn Starch 100mg

Lactose 100mg

2 mg magnesium stearate

After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.

4. Manufacture of rings

1 g of extract of Example 1 or a fraction thereof

Lactose 1.5 g

1 g of glycerin

Xylitol 0.5 g

After mixing the above components, it was prepared to be 4 g per ring in a conventional manner.

5. Manufacture of granules

150 mg of the extract of Example 1 or a fraction thereof

Soybean Extract 50mg

Glucose 200 mg

Starch 600 mg

After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 ° C. to form granules, which were then filled into fabrics.

Preparation Example 2 Preparation of Food

Foods containing the extract of the body of the present invention (magnetism) or fractions thereof were prepared as follows.

1. Preparation of flour food

0.5 to 5.0 weight of the extract of Example 1 or fractions thereof of the present invention was added to flour, and bread, cake, cookies, crackers and noodles were prepared using the mixture to prepare foods for health promotion.

2. Manufacturing of Dairy Products

5 to 10% by weight of the extract of Example 1 or fractions thereof of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.

3. Manufacture of wire

Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh using a grinder. Black beans, black sesame seeds, and perilla were also steamed and dried by a known method, and then ground to a powder having a particle size of 60 mesh. The extract of Example 1 of the present invention or a fraction thereof was concentrated under reduced pressure in a vacuum concentrator, and the dried product obtained by drying with a sprayer and a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.

The grains, seeds and the dry powder of the extract of Example 1 or fractions thereof prepared above were prepared by blending in the following ratios.

Cereals (30% by weight brown rice, 15% by weight radish, 20% by weight barley),

Seeds (7% by weight perilla, 8% by weight black beans, 7% by weight black sesame),

Dry powder of the extract of Example 1 or a fraction thereof (3% by weight),

Ganoderma lucidum (0.5% by weight),

Foxglove (0.5 wt%)

Preparation Example 3 Preparation of Beverage

1. Manufacture of health drinks

1000 mg of the extract of Example 1 or a fraction thereof

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

Add 900 ml of purified water

After mixing the above components according to the conventional healthy beverage production method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated Used to prepare the healthy beverage composition of the invention.

Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and intended use.

2. Preparation of Vegetable Juice

5 g of the extract of Example 1 or a fraction thereof of the present invention was added to 1,000 ml of tomato or carrot juice to prepare a vegetable juice for health promotion.

3. Preparation of Fruit Juice

1 g of the extract of Example 1 of the present invention or a fraction thereof was added to 1,000 ml of apple or grape juice to prepare a fruit juice for health promotion.

Preparation Example 4 Preparation of Cosmetics

Body herb (magnetization) extract of the present invention or a fraction thereof may be prepared cosmetics for the prevention and improvement of edema or dermatitis containing as an active ingredient. The present inventors prepared the cosmetic of solubilized formulations such as cosmetics and soft cosmetics of the emulsion formulations such as nutrient cosmetics, creams, essences and the like as the cosmetics.

<4-1> Cosmetic Preparation of Emulsion Formulation

Cosmetics of the emulsifier type were prepared with the composition shown in Table 1. The manufacturing method is as follows.

1) The mixture which mixed the raw materials of 1-9 was heated at 65-70 degreeC.

2) 10 was added to the mixture of step 1).

3) The mixture of the raw materials of 11-13 was heated at 65-70 degreeC, and was completely dissolved.

4) While passing through step 3), the mixture of 2) was slowly added and emulsified for 2 to 3 minutes at 8,000 rpm.

5) The raw material of 14 was dissolved in a small amount of water, and then added to the mixture of step 4) and emulsified for 2 minutes.

6) 15 to 17 of the raw materials were weighed, respectively, and added to the mixture of step 5) and emulsified for 30 seconds.

7) After emulsifying the mixture of step 6) through a degassing process to prepare a cosmetic of emulsion type by cooling to 25 ~ 35 ℃.

Composition of Emulsifying Formulations 1, 2, 3 Furtherance Emulsifier 1 Emulsifier 2 Emulsifier 3 One Stearic acid 0.3 0.3 0.3 2 Steali alcohol 0.2 0.2 0.2 3 Glyceryl Monostearate 1.2 1.2 1.2 4 Beeswax 0.4 0.4 0.4 5 Polyoxyethylene sorbitan
Monolauric acid ester 2.2 2.2 2.2 6 Methyl paraoxybenzoate 0.1 0.1 0.1 7 Paraoxybenzoic Acid Profiles 0.05 0.05 0.05 8 Cetylethylhexanoate 5 5 5 9 Triglyceride 2 2 2 10 Cyclomethicone 3 3 3 11 Distilled water To 100 To 100 To 100 12 Concentrated glycerin 5 5 5 13 Triethanolamine 0.15 0.15 0.15 14 Polyacrylic acid polymer 0.12 0.12 0.12 15 Pigment 0.0001 0.0001 0.0001 16 incense 0.10 0.10 0.10 17 Extract of Example <1-1> 0.0001 One 10

<4-2> Cosmetic Preparation of Solubilized Formulation

A cosmetic of solubilized formulation was prepared with the composition shown in Table 2. The manufacturing method is as follows.

1) Raw materials 2 to 6 were placed in raw material 1 (purified water) and dissolved using a still mixer.

2) The raw materials of 8 to 11 were put into the raw material of 7 (alcohol) and completely dissolved.

3) The mixture of step 2) was solubilized with slow addition to the mixture of step 1).

Composition of Solubilized Formulations 1, 2, 3 Furtherance Solubilized Formulation 1 Solubilized Formulation 2 Solubilized Formulation 3 One Purified water To 100 To 100 To 100 2 Concentrated glycerin 3 3 3 3 1,3-butylene glycol 2 2 2 4 EDTA-2Na 0.01 0.01 0.01 5 Pigment 0.0001 0.0002 0.0002 6 Extract of Example <1-1> 0.1 5 5 7 Alcohol (95%) 8 8 8 8 Methyl paraoxybenzoate 0.1 0.1 0.1 9 Polyoxyethylene
Hydrogenated Ester 0.3 0.3 0.3 10 incense 0.15 0.15 0.15 11 Cyclomethicone - - 0.2

1 is a graph showing the cytotoxicity of the extracts and fractions of the body sprouts (magnetism) of the present invention.

Figure 2 is a graph showing the tumor necrosis factor (TNF-α) production inhibitory effect of the extracts and fractions of the body of the present invention.

Figure 3 is a graph showing the inhibitory effect of interleukin-1β (IL-1β) production of the extracts and fractions of the body of the present invention.

Figure 4 is a graph showing the effect of inhibiting the production of nitrogen oxide (NO) of the extracts and fractions of the body of the present invention (magnetism).

Figure 5 is a graph showing the effect of inhibiting the production of prostaglandin E ₂ (PGE ₂ ) of the extracts and fractions of the body of the present invention.

Figure 6 is a graph showing that the thickness of the edema induced in the ear of the inflammatory model mouse by the extract of the body sprouts (magnetism) of the present invention.

Figure 7 is a graph showing the inhibition rate (%) of the edema induced in the ear of the inflammatory model mouse by the extract of the body sprouts (magnetism) of the present invention.

Claims (11)

A pharmaceutical composition for preventing or treating edema or dermatitis, comprising root extract of Angelica decursiva, Peucedanum decursivum , or a fraction thereof as an active ingredient. According to claim 1, wherein the root extract of the body herb extract for the prevention or treatment of edema or dermatitis, characterized in that the extract of the root dried body herb water, C ₁ ~ C ₄ lower alcohol or a mixture thereof as a solvent Pharmaceutical compositions. The pharmaceutical composition for preventing or treating edema or dermatitis according to claim 2, wherein the lower alcohol is methanol or ethanol. The method of claim 1, wherein the fraction is suspending the root extract of the body herbs in water, n-hexane (n-hexane), methylene chloride (methylene chloride, dichloromethane), ethyl acetate (ethyl acetate), n-butanol ( n-butanol) and n-hexane fraction, methylene chloride fraction, ethyl acetate fraction, n-butanol fraction or water fraction obtained by sequentially fractionation with water (H ₂ O) for the prevention or treatment of edema or dermatitis Pharmaceutical compositions. The pharmaceutical composition for preventing or treating edema or dermatitis according to claim 1, wherein the root extract of the body herb or fractions thereof inhibits the production of tumor necrosis factor (TNF-α). The pharmaceutical composition for preventing or treating edema or dermatitis according to claim 1, wherein the root extract of the body herb or fractions thereof inhibits the production of interleukin-1β (IL-1β). The pharmaceutical composition for preventing or treating edema or dermatitis according to claim 1, wherein the root extract of the body herb or fractions thereof inhibits the production of nitrogen oxides (NO). The pharmaceutical composition for preventing or treating edema or dermatitis according to claim 1, wherein the root extract of the body herb or fractions thereof inhibits the production of prostaglandin E ₂ (PGE ₂ ). The pharmaceutical composition for preventing or treating dermatitis according to claim 1, wherein the dermatitis is selected from the group consisting of hypersensitivity, allergic dermatitis, contact dermatitis, atopic dermatitis, skin allergy and urticaria. Health food composition for preventing or improving edema or dermatitis comprising root extract of Angelica decursiva, Peucedanum decursivum or fractions thereof as an active ingredient. Cosmetic composition for the prevention or improvement of edema or dermatitis comprising the root extract of Angelica decursiva, Peucedanum decursivum or fractions thereof as an active ingredient.

Images